RxDoctor Payments Data

Dilip Doctor, MD

Urology · Rego Park, NYNPI 1134291420

Payments from drug & device makers

$626in general payments, 2019–2025

Across 13 payments — averaging $48.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$189
  • GSK$125
  • AbbVie$117
  • Gilead$84
  • Astellas Pharma US Inc$63
  • Sumitomo Pharma America, Inc.$49

What the payments were for

  • Food & beverage$56290%
  • Education$6410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$626 in reported general payments places this provider in the 25th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$119,185
Medicare patients
218
Services billed
1,320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron285$145,503
ToviazFesoterodine Fumarate51$15,187
Tamsulosin Hcl263$3,181
CialisTadalafil12$3,150
Tolterodine Tartrate ErTolterodine Tartrate27$2,844
Oxybutynin Chloride ErOxybutynin Chloride158$2,776
Fesoterodine Fumarate ErFesoterodine Fumarate28$1,415
Levofloxacin161$660
Finasteride70$570
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$505
Dutasteride19$422
Bicalutamide13$285
Oxybutynin Chloride26$241
Tadalafil11$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$63$145,503285 claims
PfizerToviaz$189$15,18751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 952 urology providers in New York.

Other urology in Rego Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →